Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Oruka Therapeutics Inc ORKA

Healthcare Biotechnology

Oruka Therapeutics, Inc., formerly ARCA biopharma, Inc., is a biotechnology company. The Company is engaged in developing novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis. It is advancing a proprietary portfolio of potential antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. The... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ORKA)

ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer

GlobeNewswire May 3, 2021

ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update

GlobeNewswire March 18, 2021

ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19

GlobeNewswire December 15, 2020

ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders

GlobeNewswire December 9, 2020

AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

GlobeNewswire November 23, 2020

ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire November 2, 2020

ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19

GlobeNewswire October 7, 2020

ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality

GlobeNewswire October 5, 2020

ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19

GlobeNewswire September 21, 2020

ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19

Accesswire August 12, 2020

Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire August 5, 2020

SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators

GlobeNewswire July 7, 2020

ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering

GlobeNewswire June 3, 2020

ARCA Biopharma Announces $9.4 Million Registered Direct Offering

GlobeNewswire June 1, 2020

ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy

GlobeNewswire May 28, 2020

Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions

GlobeNewswire May 7, 2020

ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update

GlobeNewswire May 6, 2020

ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update

GlobeNewswire February 18, 2020

ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire November 6, 2019

ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium

GlobeNewswire September 12, 2019